Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma
©2020 American Association for Cancer Research..
Recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are genetic hallmarks of angioimmunoblastic T-cell lymphoma (AITL). Mice expressing the p.Gly17Val RHOA mutant on a Tet2-null background succumbed to AITL-like T-cell lymphomas due to deregulated T-cell receptor (TCR) signaling. Using these mice to investigate therapeutics for AITL, we found that dasatinib, a multikinase inhibitor prolonged their survival through inhibition of hyperactivated TCR signaling. A phase I clinical trial study of dasatinib monotherapy in 5 patients with relapsed/refractory AITL was performed. Dasatinib was started at a dose of 100 mg/body once a day and continued until days 10-78 (median day 58). All the evaluable patients achieved partial responses. Our findings suggest that AITL is highly dependent on TCR signaling and that dasatinib could be a promising candidate drug for AITL treatment. SIGNIFICANCE: Deregulated T-cell receptor signaling is a critical molecular event in angioimmunoblastic T-cell lymphoma and can be targeted with dasatinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Cancer research - 80(2020), 9 vom: 01. Mai, Seite 1875-1884 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyen, Tran B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.10.2020 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-19-2787 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30699495X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30699495X | ||
| 003 | DE-627 | ||
| 005 | 20231225124607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-19-2787 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM30699495X | ||
| 035 | |a (NLM)32107212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Tran B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2020 American Association for Cancer Research. | ||
| 520 | |a Recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are genetic hallmarks of angioimmunoblastic T-cell lymphoma (AITL). Mice expressing the p.Gly17Val RHOA mutant on a Tet2-null background succumbed to AITL-like T-cell lymphomas due to deregulated T-cell receptor (TCR) signaling. Using these mice to investigate therapeutics for AITL, we found that dasatinib, a multikinase inhibitor prolonged their survival through inhibition of hyperactivated TCR signaling. A phase I clinical trial study of dasatinib monotherapy in 5 patients with relapsed/refractory AITL was performed. Dasatinib was started at a dose of 100 mg/body once a day and continued until days 10-78 (median day 58). All the evaluable patients achieved partial responses. Our findings suggest that AITL is highly dependent on TCR signaling and that dasatinib could be a promising candidate drug for AITL treatment. SIGNIFICANCE: Deregulated T-cell receptor signaling is a critical molecular event in angioimmunoblastic T-cell lymphoma and can be targeted with dasatinib | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-vav |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a VAV1 protein, human |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Dioxygenases |2 NLM | |
| 650 | 7 | |a EC 1.13.11.- |2 NLM | |
| 650 | 7 | |a TET2 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.13.11.- |2 NLM | |
| 650 | 7 | |a Tet2 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 1.13.11.- |2 NLM | |
| 650 | 7 | |a rhoA GTP-Binding Protein |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Dasatinib |2 NLM | |
| 650 | 7 | |a RBZ1571X5H |2 NLM | |
| 700 | 1 | |a Sakata-Yanagimoto, Mamiko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujisawa, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Nuhat, Sharna Tanzima |e verfasserin |4 aut | |
| 700 | 1 | |a Miyoshi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nannya, Yasuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukumoto, Kota |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Olivier A |e verfasserin |4 aut | |
| 700 | 1 | |a Kiyoki, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Ishitsuka, Kantaro |e verfasserin |4 aut | |
| 700 | 1 | |a Momose, Haruka |e verfasserin |4 aut | |
| 700 | 1 | |a Sukegawa, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shinagawa, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Suyama, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikii, Hidekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Obara, Naoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kusakabe, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagimoto, Shintaro |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Seishi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohshima, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Chiba, Shigeru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 80(2020), 9 vom: 01. Mai, Seite 1875-1884 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2020 |g number:9 |g day:01 |g month:05 |g pages:1875-1884 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-19-2787 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2020 |e 9 |b 01 |c 05 |h 1875-1884 | ||